$VKTX đĄ
Bill Reisner new VP of Market Access at Viking Therapeutics.
He led the U.S. market access strategy for the launch of Eli Lilly's tirzepatide.
| Truist Securities đēđŽđļđģđđŽđļđģđ đđđ on đŠđļđ¸đļđģđ´ đ§đĩđ˛đŋđŽđŊđ˛đđđļđ°đ with 85$ PT